Strata Critical Medical (NASDAQ:SRTA) Raised to “Hold” at Zacks Research

Strata Critical Medical (NASDAQ:SRTA) was upgraded by stock analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings initiated coverage on Strata Critical Medical in a report on Tuesday. They set a “hold (c-)” rating on the stock. B. Riley Financial assumed coverage on Strata Critical Medical in a research note on Wednesday. They issued a “buy” rating and a $8.00 target price for the company. Finally, Craig Hallum assumed coverage on Strata Critical Medical in a research note on Wednesday. They issued a “buy” rating and a $8.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Strata Critical Medical Trading Down 2.6%

SRTA opened at $4.14 on Thursday. Strata Critical Medical has a 52 week low of $2.35 and a 52 week high of $6.02. The firm has a market cap of $357.57 million, a P/E ratio of 8.45 and a beta of 2.05.

About Strata Critical Medical

Blade Air Mobility, Inc provides air transportation alternatives to the congested ground routes in the United States. It provides its services through charter and by-the-seat flights using helicopters, jets, turboprops, and amphibious seaplanes. The company was founded in 2014 and is headquartered in New York, New York.